Wolthers Ole D, Shah Tushar
1Asthma and Allergy Clinic, Children's Clinic Randers, Randers, Denmark.
2TEVA, Global Respiratory Research and Development, Horsham, Pennsylvania.
J Aerosol Med Pulm Drug Deliv. 2015 Jun;28(3):182-8. doi: 10.1089/jamp.2014.1157. Epub 2014 Aug 28.
A combination of the inhaled corticosteroid budesonide and the long-acting β2-agonist formoterol has been formulated in a novel dry powder inhaler, Spiromax(®). The objective was to compare lower leg growth in children with asthma treated with inhaled budesonide+formoterol (BF) delivered from the Spiromax inhaler with BF from the Symbicort Turbohaler(®).
Prepubescent children with persistent asthma (n=75, aged 6-11 years) were included in a randomized, double-blind, double-dummy, placebo-controlled, three-way crossover study with active treatment and placebo periods of 2 weeks duration. Lower leg length was measured every second week. As a secondary outcome parameter, 24-hr urine was collected for assessment of free cortisol. Interventions were dry powder BF 160+9 μg twice daily (b.i.d.; delivered dose) from the Spiromax inhaler and dry powder BF 200+12 μg b.i.d. (metered dose) from the Symbicort Turbohaler.
The least squares mean difference in lower leg growth rates (LLGR) between BF Spiromax and Symbicort Turbohaler was -0.086 mm/week [95% confidence interval (CI) -0.203, 0.032]. The pre-specified non-inferiority margin was -0.200 mm/week, so the lower limit of the 95% CI was just outside this margin. The difference between BF Spiromax and placebo was -0.20 mm/week (95% CI: -0.322, 0.086); p<0.001), between Symbicort Turbohaler and placebo -0.118 mm/week (95% CI: -0.236, -0.001; p=0.048). No statistically significant differences were seen in urine free cortisol assessments.
As the lower limit of the CI of LLGR was marginally outside of the pre-specified non-inferiority margin between BF Spiromax 160+9 μg b.i.d. and Symbicort Turbohaler 200+12 μg b.i.d., non-inferiority could not be demonstrated. Further studies may be needed for comparison of systemic activity of BF Spiromax and Symbicort Turbohaler in children before firm conclusions about their comparability may be drawn.
吸入性皮质类固醇布地奈德与长效β2受体激动剂福莫特罗已被制成一种新型干粉吸入器,即思力华(Spiromax)。目的是比较使用思力华吸入器吸入布地奈德+福莫特罗(BF)治疗的哮喘儿童与使用信必可都保(Symbicort Turbohaler)吸入BF的儿童小腿生长情况。
纳入青春期前持续性哮喘儿童(n = 75,年龄6 - 11岁),进行一项随机、双盲、双模拟、安慰剂对照、三交叉研究,积极治疗期和安慰剂期均为2周。每隔一周测量小腿长度。作为次要结局参数,收集24小时尿液以评估游离皮质醇。干预措施为每日两次(bid)从思力华吸入器吸入160 + 9μg干粉BF(递送剂量),以及每日两次(bid)从信必可都保吸入200 + 12μg干粉BF(计量剂量)。
思力华BF与信必可都保BF之间小腿生长速率(LLGR)的最小二乘均值差异为-0.086mm/周[95%置信区间(CI)-0.203,0.032]。预先设定的非劣效性界值为-0.200mm/周,因此95%CI的下限刚好超出该界值。思力华BF与安慰剂之间的差异为-0.20mm/周(95%CI:-0.322,0.086;p<0.001),信必可都保与安慰剂之间为-0.118mm/周(95%CI:-0.236,-0.001;p = 0.048)。在尿液游离皮质醇评估中未发现统计学显著差异。
由于思力华160 + 9μg bid BF与信必可都保200 + 12μg bid BF之间LLGR的CI下限略超出预先设定的非劣效性界值,因此无法证明非劣效性。在得出关于它们可比性的确切结论之前,可能需要进一步研究来比较思力华BF与信必可都保在儿童中的全身活性。